Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

first-line chemotherapy in newly diagnosed multiple myeloma patients(1). Final results of the international Phase IV study, REACT (RAD001 Expanded Access Clinical Trial in RCC), evaluating Afinitor® (everolimus) tablets for the treatment of advanced renal cell carcinoma following any available vascular endothelial growth factor targeted therapy, will also be presented(1).

Notable data about Novartis treatments at ASCO include:

  • Gleevec – Two studies on Gleevec in KIT+ GIST, including a Phase III trial examining the benefit of extended adjuvant treatment for three years versus one year with Gleevec for patients following resection of their KIT+ GIST (ASCO abstract #LBA1; June 5, 1:45 - 2:00 PM CDT) and long-term follow up of the pivotal Phase II trial examining overall survival and progression-free rates in patients with metastatic and/or inoperable GIST treated for nearly 10 years with Gleevec (ASCO abstract #10016; June 4, 8:00 AM - 1:00 PM CDT).

  • INC424 – Data from two pivotal Phase III studies evaluating INC424 in patients with myelofibrosis after 48 weeks of treatment compared to best available therapy in the COMFORT-II trial (ASCO abstract #LBA6501; June 6, 9:45 - 10:00 AM CDT), and after 24 weeks of treatment compared to placebo in COMFORT-I (ASCO abstract #6500; June 6, 9:30 - 9:45 AM CDT).

  • Tasigna Mutation analysis from ENESTnd comparing Tasigna to Gleevec in patients with newly diagnosed Ph+ CML in chronic phase (ASCO abstract #6502; June 6, 10:00 - 10:15 AM CDT) and ENESTnd 24-month update (ASCO abstract #6511; June 3, 2:00 - 6:00 PM CDT).

  • Zometa Two new Myeloma IX analyses evaluate the impact of treatment initiation and duration, and baseline bone disease status, on the effect of Zometa versus clodronate on progression-free survival, overall survival and skeletal-related events when used with first-line chemotherapy in patients w
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
    (Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
    (Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
    Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
    ... 15 Prometheus Laboratories Inc., a specialty pharmaceutical ... launch of three new cancer diagnostic products: ProOnc ... Dx. Each of these tests is based on ... has a long and successful history of providing ...
    ... Oct. 15 Aethlon Medical, Inc. (OTC Bulletin Board: ... treatment of Hepatitis-C (HCV) infected patients with the Aethlon ... & Scientific Exposition of the American Society of Nephrology ... studies and Director of Nephrology at the Fortis Hospital ...
    Cached Medicine Technology:Prometheus Launches ProOnc Dx Cancer Diagnostics 2Prometheus Launches ProOnc Dx Cancer Diagnostics 3Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3
    (Date:8/22/2014)... UWDress.com, a leading online supplier of wedding dresses and women’s ... empire bridesmaid dresses to its product line. In addition ... these high quality items. All of them are now available ... , The company’s new items can definitely add beauty ... website. It is true that all its products are more ...
    (Date:8/22/2014)... CA (PRWEB) August 22, 2014 Japantown ... offering a new teeth whitening technique. Air polishing is ... cleaning appointments. , Dark teeth can be caused by ... categories: external stains and internal stains. External stains include ... can be caused by certain medications, such as tetracycline, ...
    (Date:8/22/2014)... Amy Norton HealthDay Reporter ... growing number of Americans on work disability chronically use ... Researchers found that between 2007 and 2011, about 44 ... were prescribed narcotic painkillers each year. And the percentage ... 2007 to 23 percent in 2011. Experts ...
    (Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
    (Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
    Breaking Medicine News(10 mins):Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
    ... to bring an end to the double–penalty system for health trusts ... a health trust falls into deficit, not only is it penalized ... money is cut off from its allocated funds from the ensuing ... health trusts find it virtually impossible to balance accounts and have ...
    ... Millions of Americans whose vision is slowly ebbing due to ... the lowly neural progenitor cell may be useful for restoring ... rats, neural progenitor cells derived from human fetal stem cells ... degenerative eye disease similar to the kinds of diseases that ...
    ... control high blood pressure and new drugs that target ... have designed two promising new cardiovascular treatment approaches, a ... to lower high blood pressure and a therapeutic hybrid ... ,In the process, they have overcome ...
    ... new study finds the popular anti-clotting drug clopidogrel (Plavix) when ... safe without any adverse bleeding event.// ,The ... 56th Annual Scientific Session on March 27 at 9 am ... aspirin, will not worsen bleeding after off-pump heart bypass surgery. ...
    ... multi-center study concludes that women with a recent diagnosis of ... opposite breast.// ,This study was conducted by ... ,The international research team found that MRI, or ... 30 of 969 women (3.1 percent) who had recently been ...
    ... considering vaccinating young girls against a virus that causes cervical ... Robert Koch-Institute in Germany has recommended the universal vaccination of ... ,The Italian Ministry of Health has announced that vaccination of ... as regional vaccination centers are prepared. ,Government ...
    Cached Medicine News:Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Hormone-based Heart Pill to Control High Blood Pressure 2Health News:Hormone-based Heart Pill to Control High Blood Pressure 3Health News:Plavix Safe During and After Heart Bypass 2Health News:MRI Screening of Other Breast Crucial for Patients Diagnosed With Cancer in One Breast 2
    ... Thermo Scientific Finnpipette Dispenser cover all volumes ... very high consistency, precision and reproducibility, due ... The Finnpipette Dispenser range is the latest ... manual liquid handling products, offering users reliability ...
    ... compact, mobile femtosecond surgical laser, has been ... for a wide spectrum of applications in ... demand of refractive surgeons for an "all-Laser ... efficient LASIK work-flow. The solution by Ziemer ...
    ... EHEC is the first one-step 20 minutes rapid ... and 2 produced by Enterohemorrhagic Escherichia coli in ... overnight enrichment of fecal specimens and detects all ... The separate result for Toxin 1 and 2 ...
    Inquire...
    Medicine Products: